Antimicrobial activity of mul-1867, a novel antimicrobial compound, against multidrug-resistant Pseudomonas aeruginosa

Annals of Clinical Microbiology and Antimicrobials

Volumn 15, Issue 1, 2016, Pages

  Tetz, George ^a   Vikina, Daria ^b   Tetz, Victor ^b  

^a TGV Laboratories LLC   (United States)

^b Institute of Human Microbiology   (United States)

Author keywords

Biofilms; Cystic fibrosis; Mucoid; Multidrug resistant; Non mucoid; P. aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT; MUL 1867; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BIOFILM; BROTH MACRODILUTION METHOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DILUTION; DRUG CONCENTRATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; MDCK CELL LINE; MINIMUM BIOFILM ELIMINATING CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MTT ASSAY; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; VENTILATOR ASSOCIATED PNEUMONIA; ANIMAL; CELL LINE; CHEMISTRY; COMPLICATION; DOG; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; CELL LINE; CYSTIC FIBROSIS; DOGS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84962616567     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-016-0134-4     Document Type: Article

References (31)

1. Garcia-Vidal C, Almagro P, Romaní V, Rodríguez-Carballeira M, Cuchi E, Canales L, Garau J, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J. 2009;34:1072-8.
2. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Hoiby N, et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol. 2012;10:841-51.
3. Peña C, Gómez-Zorrilla S, Oriol I, Tubau F, Dominguez MA, Pujol M, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis. 2013;32:413-20.
4. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749-56.
5. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am J Respir Crit Care Med. 2011;183:1674-9.
6. Schelstraete P, Haerynck F, Van daele S, Deseyne S, De Baets F. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa. J Cyst Fibros. 2013;12:1-8.
7. Domenech A, Puig C, Martí S, Santos S, Fernández A, Calatayud L, et al. Infectious etiology of acute exacerbations in severe COPD patients. J Infect. 2013;67:516-23.
8. Owlia P, Nosrati R, Alaghehbandan R, Lari AR. Antimicrobial susceptibility differences among mucoid and non-mucoid Pseudomonas aeruginosa isolates. GMS Hyg Infect Control. 2014;9:13.
9. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996;60:539-74.
10. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-22.
11. Tetz GV, Artemenko NK, Tetz VV. Effect of DNase and antibiotics on biofilm characteristics. Antimicrob Agents Chemother. 2009;53:1204-9.
12. Lopes SP, Ceri H, Azevedo NF, Pereira MO. Antibiotic resistance of mixed biofilms in cystic fibrosis: impact of emerging microorganisms on treatment of infection. Int J Antimicrob Agents. 2012;40:260-3.
13. Tetz VV, Korobov VP, Artemenko NK, Lemkina LM, Panjkova NV, Tetz GV. Extracellular phospholipids of isolated bacterial communities. Biofilms. 2004;1:149-55.
14. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95-108.
15. Breidenstein EB, de la Fuente-Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19:419-26.
16. Rodríguez-Martínez JM, Pascual A. Antimicrobial resistance in bacterial biofilms. Rev Med Microbiol. 2006;17:65-75.
17. Döring G, Flume P, Heijerman H, Elborn JS. Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11:461-79.
18. Morosini MI, García-Castillo M, Loza E, Pérez-Vázquez M, Baquero F, Cantón R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol. 2005;43:4480-5.
19. Reiter KC, Sambrano GE, Villa B, Paim T, Oliveira C, d'Azevedo PA. Rifampicin fails to eradicate mature biofilm formed by methicillin-resistant Staphylococcus aureus. Rev Soc Bras Med Trop. 2012;45:471-4.
20. Tetz G, Tetz V. In vitro antimicrobial activity of a novel compound, Mul-1867, against clinically important bacteria. Antimicrob Resist Infect Control. 2015;4:45.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement (M100-S21). Clinical and Laboratory Standards Institute, Wayne 2011.
22. Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guideline (M26-A). Wayne: Clinical and Laboratory Standards Institute; 1999.
23. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, ninth edition (M07-A9). Wayne: Clinical and Laboratory Standards Institute; 2012.
24. Sieuwerts AM, Klijn JG, Peters HA, Foekens JA. The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem. 1995;33:813-23.
25. Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, et al. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med. 2014;190:289-97.
26. Lam JC, Somayaji R, Surette MG, Rabin HR, Parkins MD. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response. BMC Infect Dis. 2015;15:145.
27. Flume PA, VanDevanter DR. Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev. 2015;85:1-6.
28. Fricks-Lima J, Hendrickson CM, Allgaier M, Zhuo H, Wiener-Kronish JP, Lynch SV, et al. Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients. Int J Antimicrob Agents. 2011;37:309-15.
29. Schülin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother. 2002;49:403-6.
30. Messiaen AS, Nelis H, Coenye T. Investigating the role of matrix components in protection of Burkholderia cepacia complex biofilms against tobramycin. J Cyst Fibros. 2014;13:56-62.
31. Hengzhuang W, Ciofu O, Yang L, Wu H, Song Z, Oliver A, et al. High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2013;57:196-204.